Detalhe da pesquisa
1.
The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer.
Bioinformatics
; 35(16): 2738-2748, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30615123
2.
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
BMC Cancer
; 18(1): 314, 2018 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562902
3.
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
Future Oncol
; 14(19): 1897-1908, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29451020
4.
Role of microtubules in attenuation of PepG-induced vascular endothelial dysfunction by atrial natriuretic peptide.
Biochim Biophys Acta
; 1852(1): 104-19, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25445540
5.
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
BMC Cancer
; 16: 568, 2016 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27480287
6.
Attenuation of lipopolysaccharide-induced lung vascular stiffening by lipoxin reduces lung inflammation.
Am J Respir Cell Mol Biol
; 52(2): 152-61, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24992633
7.
A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report.
Transl Lung Cancer Res
; 13(5): 1163-1168, 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38854944
8.
Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer.
Cancers (Basel)
; 15(5)2023 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900386
9.
Integration of artificial intelligence in lung cancer: Rise of the machine.
Cell Rep Med
; 4(2): 100933, 2023 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738739
10.
Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status.
Brain Sci
; 13(7)2023 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37508989
11.
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
JCO Precis Oncol
; 7: e2200445, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37656950
12.
Clinical Network Systems Biology: Traversing the Cancer Multiverse.
J Clin Med
; 12(13)2023 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37445570
13.
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Front Oncol
; 13: 1064169, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36860308
14.
Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
Cold Spring Harb Mol Case Stud
; 9(2)2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37160318
15.
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine.
J Clin Med
; 12(5)2023 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36902723
16.
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
Sci Adv
; 9(41): eade3816, 2023 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37831779
17.
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
J Clin Med
; 11(5)2022 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35268520
18.
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Cancers (Basel)
; 14(19)2022 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230855
19.
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans.
J Clin Med
; 11(22)2022 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36431215
20.
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
Cell Rep Med
; 2(1): 100186, 2021 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33521700